Germany To Increase Data Requirements For Pricing Orphan And Other Drugs
Executive Summary
A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.
You may also be interested in...
EU Rare Disease Policy Needs To Help Revive Abandoned Candidates & Repurpose Existing Drugs
The EU must adopt a more comprehensive policy on rare diseases to increase the number of orphan drugs and address access challenges, says EURORDIS’ chief executive Yann Le Cam.
Zolgensma First To Be Subject To New German Data Collection Rules
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
Zolgensma First To Be Subject To New German Data Collection Rules
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.